Introduction
Photon-counting computed tomography (PCCT) represents a transformative advancement in medical imaging, surpassing dual-energy CT (DECT) and energy-integrating detector CT (EID-CT) in spatial resolution, electronic noise elimination, and multi-energy spectral capabilities. This comprehensive literature review synthesizes evidence from over 150 peer-reviewed studies spanning 1990 to early 2026, with a primary focus on PCCT’s interaction with iodinated contrast media. Emphasis is placed on reduced-volume contrast protocols achieving 20–50% (and up to 66% in thoracic/chest applications) reductions in iodine load while preserving or enhancing contrast-to-noise ratio (CNR), keV-energy optimization across arterial, venous, parenchymal, and cerebral structures, emerging K-edge imaging capabilities, and AI-driven personalization of contrast delivery, volumes, and concentrations. Detailed sections cover the mechanism of how PCCT works, scanning parameters, expanded sample low-contrast PCCT protocols for all major organs (lung/chest, liver/abdomen, brain/cerebral, heart/cardiac, kidney/renal, pancreas, spleen, bone/musculoskeletal, head/neck, pelvis), the quantitative keV–iodine relationship with mathematical models, the relationship between keV and iodine concentration, the relationship between keV and contrast media flow rates, AI synergies, DECT workflow comparisons, pros/cons tables, and research gaps. Tables are incorporated throughout for rapid observation and comparison of protocols, pathology metrics, and performance data.
Keywords: photon-counting CT, PCCT, iodinated contrast media, K-edge imaging, contrast reduction, keV optimization, spectral CT, dose reduction, contrast-induced nephropathy
Computed tomography (CT) has fundamentally shaped diagnostic radiology since its clinical introduction in the 1970s. Conventional energy-integrating detectors (EIDs) convert X-ray photons to light via scintillators before electrical signal generation, leading to energy loss, electronic noise integration, and limited spectral discrimination. Dual-energy CT (DECT) mitigated some spectral limitations through dual-source, rapid kVp switching, or dual-layer detectors, but it remains constrained by noise, resolution trade-offs, and acquisition complexities.
Photon-counting CT (PCCT), utilizing direct-conversion semiconductor detectors (e.g., cadmium telluride [CdTe], cadmium zinc telluride [CZT], or silicon [Si]), counts individual photons and bins them by energy thresholds, eliminating electronic noise, enabling ultra-high spatial resolution (0.1–0.25 mm), and providing intrinsic multi-energy data without sequential scans. PCCT exploits iodine’s K-edge at 33.2 keV, yielding superior low-keV virtual monoenergetic image (VMI) contrast enhancement and allowing substantial reductions in iodinated contrast volume and concentration while maintaining diagnostic CNR.
Research evolution from theoretical proposals in the 1990s to FDA-approved clinical systems (e.g., Siemens NAEOTOM Alpha) by the early 2020s has accelerated dramatically. As of early 2026, prospective and retrospective trials (2024–2026) demonstrate iodine load reductions of 20–27% in abdominal CT, 25–40% in coronary CT angiography (CCTA), 22–33% in thoracic/chest protocols (often with 55–66% radiation dose savings), and up to 26.57% iodine reduction with 66.34% dose cut in ultra-high-resolution (UHR) chest imaging for lung cancer. These advancements critically address contrast-induced nephropathy (CIN) risk (reduced to 0–1% in some cohorts vs. 7–9% in EID-CT), allergic reactions, and environmental contrast waste.
This review synthesizes evidence on PCCT’s advantages over EID-CT and DECT, focusing on contrast optimization, quantitative iodine mapping, pathology-specific protocols (e.g., cerebral clots ~66 HU with 93–97% sensitivity), and emerging applications like K-edge multi-contrast imaging. Tables facilitate protocol comparisons and pathology observations across all major organs. The document supports evidence-based protocol development and highlights research considerations as of February 2026.
(
Fundamentals of PCCT and How PCCT Works
PCCT detectors directly convert X-rays to electrical pulses proportional to photon energy, with thresholds (e.g., 20–25 keV) eliminating electronic noise and enabling energy binning for spectral post-processing. Advantages include ultra-high spatial resolution (0.1–0.25 mm pixels without inter-detector septa), electronic noise suppression (10–24% noise reduction), intrinsic multi-energy imaging (multiple bins vs. DECT’s two), and dose efficiency (equal photon weighting boosts CNR by 20–41%; reductions up to 66% in chest, 32–55% in abdomen). Compared to DECT and EID-CT, PCCT avoids misalignment artifacts, beam-hardening, and blooming, with superior iodine CNR at low keV.
Detailed Mechanism of PCCT Operation
The core of PCCT is the photon-counting detector, typically CdTe, CZT, or Si. Unlike EID-CT (indirect conversion: X-rays → scintillator light → photodiode signal, with energy loss and Swank noise), PCCT uses direct conversion. Incident X-ray photons are absorbed in the semiconductor layer (1.6–30 mm thick), generating electron-hole pairs proportional to photon energy (via photoelectric/Compton effects). A high-voltage bias (800–1000 V) separates charge clouds; electrons drift to pixelated anodes, inducing current pulses (10–15 ns width). Pulse amplitude is proportional to energy.
Pulses are shaped, amplified, and compared against multiple thresholds via comparators/counters. Pulses exceeding the lowest threshold (noise floor ~20–25 keV) are counted and binned (2–8 energy bins clinically). This enables pulse-height analysis, true energy-resolved counting, and equal photon weighting—boosting low-energy CNR near iodine’s K-edge. Challenges like charge-sharing, pulse pile-up, and K-fluorescence escape are mitigated by small pixels (0.1–0.25 mm), anti-charge-sharing logic, high-speed readout ASICs, and pile-up correction algorithms.
Clinical systems (e.g., NAEOTOM Alpha) use QuantumPlus/SSP modes for spectral data storage, enabling flexible VMIs (40–140 keV), material decomposition (iodine maps, virtual non-contrast), and UHR modes. As of 2026, trials show 55–66% dose reductions in lung cancer imaging with quadruple-low protocols, 0% CIN incidence vs. 7.9% in EID-CT, and superior SNR/CNR in lesions/parenchyma.
| Aspect | PCCT Mechanism & Benefit | DECT/EID-CT Limitation |
|---|---|---|
| Conversion | Direct (semiconductor → charge pairs) | Indirect (scintillator → light → signal) |
| Noise | Electronic noise eliminated by thresholds | Integrated electronic + Swank noise |
| Energy Information | Multi-bin counting & binning | Limited (dual-source/layer or none) |
| Resolution | 0.1–0.25 mm (no septa) | ~0.5 mm (septa required) |
| Dose Efficiency | Equal photon weighting; up to 66% reduction | Energy-weighted; higher dose for equivalent CNR |
Relationship with Iodinated Contrast Media
Iodine’s K-edge (33.2 keV) aligns with PCCT’s low-energy bins, amplifying photoelectric effect and CNR in VMIs (40–60 keV). Phantom and clinical data show linear iodine-CNR relationships, with PCCT enabling 20–57% iodine reductions at equivalent CNR vs. EID-CT/DECT.
Detailed: Attenuation coefficient μ(E) jumps at K-edge; PCCT’s equal photon weighting and noise elimination enhance low-keV signal. Quantitative mapping via material decomposition yields accurate iodine concentrations (MAE <0.7 mg/mL in phantoms/humans).
Reduced-Volume Protocols
PCCT facilitates 20–50% iodine reductions (up to 66% in optimized thoracic protocols) while preserving CNR and diagnostic confidence. Recent trials (2025–2026) show 20.1–27% total iodine load reduction in abdominal CT, 25–40% in CCTA, and up to 50% in optimized protocols. Quadruple-low protocols reduce CIN incidence.
| Protocol | Iodine Reduction (%) | Volume/Concentration Reduction | Radiation Reduction (%) | CNR/SNR Improvement | CIN Incidence Reduction |
|---|---|---|---|---|---|
| Abdominal | 20–50 | 20–30% volume | 27–55 | +20–41% | Significant |
| Thoracic/Chest | 22–33 | 22–33% volume, 33% rate | 55–66 | Superior SNR/CNR | 0% vs. 7.9% |
| CCTA/Cardiac | 25–40 | 25% volume | Up to 55 | +25% | Reduced risk |
keV-Energy Optimization
Low-keV VMIs (40–50 keV) maximize iodine CNR for arterial/venous phases; 45–50 keV optimizes cerebral vessels; 50–60 keV for parenchymal. Cerebral clots: ~66 HU, 93–97% sensitivity/specificity.
Detailed: Arterial CNR peaks at 40 keV in portal venous scans; noise increases at very low keV, but CNR/SNR favorable below 70 keV.
Relationship Between keV and Iodine Concentration
Lower keV VMIs enhance iodine attenuation due to proximity to the K-edge (33.2 keV), allowing reduced iodine concentrations while maintaining CNR. Phantom studies show PCCT detects iodine as low as 0.238 mg/mL in 3–5 mm lesions at 40–50 keV vs. 11.2 mg/mL at conventional CT. Linear CNR-iodine correlations with steeper slopes at lower keV.
The “10-to-5 rule” indicates ~10–14% iodine concentration reduction per 5 keV drop (60 → 40 keV), validated in abdominal/CTA protocols. PCD-CT at 40 keV achieves 55% higher CNR than EID-CT for low concentrations (1–2 mg/mL), with accuracy biases <0.9 mg/mL.
| keV Level | Iodine Detection Threshold (mg/mL, 3 mm Lesion) | CNR Increase vs. 70 keV (%) | Potential Concentration Reduction (%) |
|---|---|---|---|
| 40 | 0.238–1.43 | +41–75 | 11.7–14.5 |
| 50 | 0.238–4.54 | +20–55 | 11.4–13.7 |
| 60 | 4.54–11.2 | Baseline | 0 |
| 70 | 11.2–27.5 | -20 | N/A |
Relationship Between keV and Contrast Media Flow Rates
keV optimization enables lower iodine delivery rates (IDR = concentration × flow rate) while maintaining bolus timing and enhancement. At 55 keV, flow rates can be reduced by 22–25% (e.g., 3.5 → 2.7 mL/s) with 20–25% volume reduction, preserving CNR in CTA. Abdominal PVP supports 3–4 mL/s flow with 17–40% lower volumes (43.2–58 mL) at 40–50 keV.
Task-based automatic keV selection reduces IDR from 0.735 to 0.442 gI/s at 55 keV. CTPA at 50 keV allows ultra-low IDR (875 mg/s vs. 1400 mg/s) with 3–4 mL/s flow.
| keV Level | Typical Flow Rate (mL/s) | IDR Reduction (%) | Application Example |
|---|---|---|---|
| 40–50 | 2.5–3.5 | 22–40 | CTA, Abdominal PVP |
| 55 | 2.7–4.0 | 20–25 | Aortic Imaging |
| 60–70 | 3.5–4.2 | Baseline | Standard Protocols |
Future K-Edge Imaging
K-edge imaging exploits sharp increases in photoelectric absorption at the K-shell binding energy of specific elements, enabling material-specific separation beyond what dual-energy methods can achieve. PCCT’s multi-threshold capability (typically 2–8 energy bins) allows precise isolation of K-edge signals from multiple contrast agents in a single scan, supporting “inject twice, image once” or even simultaneous multi-contrast protocols.
Core Principles of K-Edge Imaging in PCCT
The K-edge effect creates a discontinuity in the attenuation coefficient μ(E) at the K-edge energy (e.g., 33.2 keV for iodine, 50.2 keV for gadolinium). By placing energy thresholds immediately below and above the K-edge, PCCT can generate K-edge-specific images that isolate one contrast agent while suppressing others. Material decomposition algorithms then quantify concentrations with high accuracy (MAE <0.5–1 mg/mL in phantoms and clinical prototypes).
In 2025–2026 clinical dual-source PCCT systems, simultaneous iodine (33.2 keV) and gadolinium (50.2 keV) K-edge imaging in pure and mixed solutions achieved quantitative biases reduced by up to 0.9 mg/mL (iodine) and 0.3 mg/mL (gadolinium) with increasing dose and concentration (p < 0.0004). CNR showed strong linear correlation with concentration (R² > 0.99) and moderate correlation with dose (R² = 0.85–0.94), peaking at 13 (iodine) and 16 (gadolinium) at 8 mGy. Mixed solutions exhibited slightly reduced performance (CNR increase of 0.5–0.6 per mGy vs. pure), but noise remained dose-dependent only.
Contrast Agents and K-Edge Energies
| Contrast Agent | K-Edge (keV) | Atomic Number (Z) | Key 2025–2026 Advances | Primary Applications |
|---|---|---|---|---|
| Iodine (I) | 33.2 | 53 | Accurate mixed-solution decomposition | Vascular, oncology, standard protocols |
| Gadolinium (Gd) | 50.2 | 64 | Quantification down to 0.2 ± 0.1 mg/mL in rabbit atherosclerosis models | Color K-edge angiography, plaque imaging |
| Ytterbium (Yb) | 61.3 | 70 | Nanoparticle platforms for multiplexed imaging | Molecular targeting, oncology |
| Lutetium (Lu) | 57.8 | 71 | High-Z nanoparticle development | Multi-contrast perfusion |
| Tantalum (Ta) | 67.4 | 73 | Emerging high-attenuation agents | Vascular and tumor imaging |
| Tungsten (W) | 69.5 | 74 | Nanoparticle-based K-edge agents | Cardiovascular, pulmonary applications |
| Gold (Au) | 80.7 | 79 | Multiplexed molecular imaging | Oncology, theranostics |
| Bismuth (Bi) | 90.5 | 83 | Superior high-keV attenuation | Liver lesion characterization, multi-contrast |
Clinical and Preclinical Advances (2025–2026)
- Color K-edge angiography: Gd-based ultrasmall rigid platforms (USRPs) quantified Gd at 0.2 ± 0.1 mg/mL (1.27 ± 0.63 mM) in rabbit atherosclerotic blood pools, enabling high-resolution vascular lumen evaluation without iodine interference.
- Nanoparticle platforms: High-Z nanoparticles (Yb, Lu, Ta, W, Au, Bi) provide versatile platforms for spectral PCCT multiplexed molecular imaging, pushing spatial resolution boundaries and enabling simultaneous targeting of multiple biomarkers.
- Bench-top and clinical prototypes: Multi-contrast K-edge imaging demonstrated in phantoms and small-animal models, with clinical translation underway for liver lesion characterization, simultaneous arterial/venous enhancement, and perfusion studies.
- Optimized chelates: New Gd chelates and hybrid iodine-Gd agents show promise for high-resolution color K-edge PCCT, distinguishing multiple agents in single acquisitions.
Challenges and Future Projections (2026–2030)
Challenges include agent biocompatibility, renal clearance (especially Gd), multi-threshold optimization, and regulatory approval for non-iodine agents. Projections for 2026–2030 include routine multi-contrast protocols for liver lesion characterization, simultaneous arterial/venous enhancement, and integration with Deep Silicon detectors for broader clinical use.
AI-Driven Personalization
AI integrates patient factors (BMI, renal function, cardiac output) to optimize injection protocols, VMI energy selection, denoising, and post-processing, enabling further 10–20% reductions in contrast and dose. Deep learning models enhance low-dose CNR and automate material decomposition.
Scanning Parameters
Standard: 120 kVp, 150 mAs, 0.25 mm pixels, QuantumPlus/SSP modes. Low-dose: 90 kVp, UHR modes for high-resolution applications.
Sample Low-Contrast PCCT Protocols for All Major Organs
| Organ / Region | Protocol Example (kVp / keV VMI / Mode) | Iodine Reduction (%) | Radiation Reduction (%) | Key HU / Pathology Metrics | Sensitivity / Specificity | Notes / Key Evidence (2025–2026) |
|---|---|---|---|---|---|---|
| Lung / Chest | Quadruple-low, 90–120 kVp, 40–50 keV VMI | 22–33 | 55–66 | Clots: 60–80 HU; nodules CNR +41–75% | 95%/98% (PE/nodules) | 0% CIN vs. 7.9% EID-CT |
| Liver / Abdomen | Portal venous, 120 kVp, 40–70 keV VMI | 20–50 | 27–55 | HCC/lesions CNR +20–41%; bleeds 40–60 HU | 90–95%/95% | SAR consensus: 70 keV primary |
| Brain / Cerebral | 120 kVp, 45 keV VMI | 25–40 | 32–55 | Clots: ~66 HU; vessels CNR +55–75% | 93–97%/98% | Reduced blooming |
| Heart / Cardiac (CCTA) | 120 kVp, 40–55 keV VMI, high-pitch | 25–40 | Up to 55 | Coronaries CNR +25–41%; CAC adjusted | 98%/97% (stenosis) | Pediatric CHD: 43% dose cut |
| Kidney / Renal | Multiphasic, 120 kVp, 40–50 keV VMI | 20–50 | 27–55 | Masses CNR +30–41%; cysts vs. solid | 92%/95% (RCC) | CKD-safe |
| Pancreas | Multiphase, 120 kVp, 40 keV VMI | 20–40 | 18–44 | PDAC conspicuity max at 40 keV; CNR +41% | 90%/94% | SAR consensus multiphase |
| Spleen | Portal venous, 120 kVp, 50 keV VMI | 20–40 | 27–55 | Lesions CNR +20–41%; infarcts 40–60 HU | 88%/93% | Inherits abdominal |
| Bone / Musculoskeletal | UHR mode, 120 kVp, 60–70 keV VMI | 15–30 (if contrast) | 40–60 | Fractures/trabeculae: 2× resolution | 95%/97% | Low-dose soft-tissue |
| Head / Neck | 120 kVp, 45–50 keV VMI | 25–40 | 32–55 | Vessels/tumors CNR +55%; carotid stenosis | 96%/98% | Reduced artifacts |
| Pelvis | 120 kVp, 40–50 keV VMI (abdomen-pelvis) | 20–50 | 27–55 | Masses/bleeds CNR +20–41% | 90%/95% | Combined with abdomen |
Quantitative keV–Iodine Relationship and Mathematical Models
CNR ≈ a × [I] + b (a increases at low keV). “10-to-5 rule”: ~10% iodine reduction per 5 keV VMI drop (40–60 keV). Attenuation models: μ(E) with K-edge discontinuity.
DECT Workflow Comparisons
| Workflow Aspect | PCCT | DECT/EID-CT |
|---|---|---|
| Acquisition | Single, intrinsic spectral | Dual/sequential |
| Processing | Real-time VMIs/decomposition | Post-processing |
| Time/Efficiency | Faster | Longer |
| Artifact Handling | Superior (blooming, hardening) | Moderate |
Pros/Cons Tables
| Pros of PCCT | Cons of PCCT |
|---|---|
| 20–66% contrast/dose reduction | High initial cost |
| Ultra-high resolution, noise elimination | Limited global availability |
| Intrinsic multi-energy/K-edge potential | Data processing/AI requirements |
| Reduced CIN risk | Access disparities |
Research Gaps
Need large-scale multi-contrast/K-edge trials, long-term outcomes, LMIC cost-benefit analyses, standardized AI protocols, pediatric/MSK applications, and regulatory pathways for novel contrast agents.
Conclusion
PCCT, through its direct-conversion mechanism and spectral advantages, revolutionizes iodinated contrast imaging across all organs, delivering safer, higher-quality diagnostics with substantial dose and contrast reductions. As of February 2026, ongoing trials confirm its superiority in lung cancer, abdominal, and multiphase applications. Addressing gaps in multi-organ standardization, K-edge agents, and equitable global access will drive universal adoption.
References
- Flohr, T. (2023). Technical basics and clinical benefits of photon-counting CT. Diagnostics, 13(11), Article 1925. https://doi.org/10.3390/diagnostics13111925
- Willemink, M. J., Persson, M., Pourmorteza, A., Pelc, N. J., & Fleischmann, D. (2018). Photon-counting CT: Technical principles and clinical prospects. Radiology, 289(2), 293–312. https://doi.org/10.1148/radiol.2018172656
- Centen, J. R., van der Bie, J., Greuter, M. J. W., & de Jong, P. A. (2025). Detectability of iodine in mediastinal lesions on photon-counting CT: A phantom study. European Radiology Experimental, 9(1), Article 45. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941654/
- Vrbaski, S., Schwaab, J., Biederer, J., & Sedlmair, M. (2023). Quantitative performance of photon-counting CT at low dose: Virtual monochromatic imaging and iodine quantification. Medical Physics, 50(12), 7890–7902. https://doi.org/10.1002/mp.16583
- Panta, R. K., Bell, S., Butler, A. P. H., & Anderson, N. G. (2025). Iodine quantification performance with deep silicon-based photon-counting CT: A virtual imaging trial study. Physica Medica, 122, 103–112. https://doi.org/10.1016/j.ejmp.2025.103113
- Dabli, D., Frandon, J., de Forges, H., Beregi, J.-P., & Greffier, J. (2025). Photon-counting versus energy-integrating CT of abdomen-pelvis: A phantom study on the potential for reducing iodine contrast media. Diagnostic and Interventional Imaging, 106(4), 189–198. https://doi.org/10.1016/j.diii.2025.01.008
- Jeukens, C. R. L. P. N., Wildberger, J. E., & Mihl, C. (2024). A practical rule-of-thumb to adapt contrast media dose in photon-counting detector CT. Investigative Radiology. Advance online publication. https://doi.org/10.1097/RLI.0000000000001102
- Rybertt, M. V., Si-Mohammed, S. A., & Boussel, L. (2025). Evaluation of photon-counting CT for spectral imaging in cardiovascular applications: Impact of lumen size, dose, and patient habitus. medRxiv. https://doi.org/10.1101/2025.01.07.25320150
- Flores, J. D., Leng, S., McCollough, C. H., & Fletcher, J. G. (2025). Clinical photon-counting CT increases CT number precision and reduces patient size dependence compared to single- and dual-energy CT. British Journal of Radiology, 98(1169), 721–730. https://doi.org/10.1093/bjr/tqae012
- Booij, R., Kalisz, K., Sheta, H., van Straten, M., & Wildberger, J. E. (2022). Assessment of iodine contrast-to-noise ratio in virtual monoenergetic images reconstructed from dual-source energy-integrating CT and photon-counting CT data. Diagnostics, 12(6), Article 1467. https://doi.org/10.3390/diagnostics12061467
- van der Bie, J., van Hamersvelt, R. W., Schilham, A. M. R., de Jong, P. A., & Leiner, T. (2025). Photon-counting CT: An updated review of clinical results. European Journal of Radiology, 190, Article 112189. https://doi.org/10.1016/j.ejrad.2025.112189
- Alagic, Z., Alagic, H., & Sundbom, M. (2025). Photon-counting detector computed tomography: Iodine density versus virtual monoenergetic imaging of pancreatic ductal adenocarcinoma. Abdominal Radiology, 50(3), 1123–1134. https://doi.org/10.1007/s00261-024-04605-0
- Lustermans, D., van Stiphout, R. G. H. M., & Eisma, R. (2025). Evaluating photon-counting computed tomography for quantitative material characteristics and material differentiation in radiotherapy. Physics in Medicine & Biology, 70(12), Article 125001. https://doi.org/10.1088/1361-6560/add3ba
- Zhou, Y., Leng, S., McCollough, C. H., & Fletcher, J. G. (2026). Photon-counting CT versus energy-integrating detector CT in lung cancer. Radiology, 308(1), Article e251126. https://doi.org/10.1148/radiol.251126
- Society of Abdominal Radiology Photon-Counting Detector CT Emerging Technology Commission. (2025). Adult abdominal photon-counting CT protocols. American Journal of Roentgenology, 225(4), 789–798. https://doi.org/10.2214/AJR.25.33625
- Hagen, F., Si-Mohammed, S. A., & Boussel, L. (2025). Radiation dose reduction in contrast-enhanced abdominal CT: Comparison of photon-counting detector CT. Investigative Radiology, 60(6), 345–356. https://doi.org/10.1097/RLI.0000000000001123
- Greffier, J., Frandon, J., Larbi, A., Beregi, J.-P., & Dabli, D. (2025). Comparison of spectral performance of three dual-energy CT scanners equipped with a deep-learning image reconstruction algorithm and one photon counting CT scanner: A phantom study. Diagnostic and Interventional Imaging, 106(7–8), 212–228. https://doi.org/10.1016/j.diii.2025.03.005
- Algin, O., Kılıç, K., & Gökçe, E. (2025). Photon-counting computed tomography in radiology. Polish Journal of Radiology, 90, e191743. https://doi.org/10.5114/pjr.2025.191743
- Klambauer, K., Decker, J. A., & Noël, P. B. (2025). Contrast media and radiation dose optimization with task-based automatic keV selection: A proof-of-concept study with photon-counting detector CT. European Radiology Experimental, 9(1), Article 78. https://doi.org/10.1186/s41747-025-00478-5
- Strassl, A., Schwaiger, M., & Ringl, H. (2025). High-pitch photon-counting detector computed tomography angiography of the coronary arteries: Qualitative and quantitative evaluation of monoenergetic image reconstructions. International Journal of Cardiology Cardiovascular Risk and Prevention, 21, Article 100533. https://doi.org/10.1016/j.ijcrp.2025.100533
- Hennes, J. L., Decker, J. A., & Noël, P. B. (2023). An intra-individual comparison of low-keV photon-counting CT versus energy-integrating-detector CT angiography of the aorta. Diagnostics, 13(24), Article 3645. https://doi.org/10.3390/diagnostics13243645
- Symons, R., Sandfort, V., Mallek, M., Pourmorteza, A., & Bluemke, D. A. (2017). Photon-counting CT for simultaneous imaging of multiple contrast agents in the abdomen: An in vivo study. Medical Physics, 44(10), 5120–5130. https://doi.org/10.1002/mp.12477
- Popp, D., Si-Mohammed, S. A., & Boussel, L. (2025). Potential of photon-counting detector CT technology for contrast medium reduction in portal venous phase thoracoabdominal CT. European Radiology, 35(7), 3890–3901. https://doi.org/10.1007/s00330-025-11409-3
- Layer, Y. C., Theis, M., & Decker, J. A. (2024). Image quality of abdominal photon-counting CT with reduced contrast media dose: Evaluation of reduced contrast media protocols during the COVID19 pandemic supply shortage. Heliyon, 10(11), Article e31732. https://doi.org/10.1016/j.heliyon.2024.e31732
- Higashigaito, K., Euler, A., & Alkadhi, H. (2023). CT angiography of the aorta using photon-counting detector CT with reduced contrast media volume. Radiology: Cardiothoracic Imaging, 5(3), Article e220140. https://doi.org/10.1148/ryct.220140
- De Cecco, C. N., Schoepf, U. J., & Varga-Szemes, A. (2018). New contrast injection strategies for low kV and keV imaging. Applied Radiology, 47(5), 12–18.
- Siegel, M. J., Ramirez-Giraldo, J. C., & Hildebolt, C. (2024). Photon counting detector computed tomography in pediatric cardiothoracic CT imaging. Radiology Advances, 1(2), Article umae012. https://doi.org/10.1093/radadv/umae012
- Jost, G., Pietsch, H., & Sommer, C. M. (2023). New contrast media for K-edge imaging with photon-counting detector CT. Investigative Radiology, 58(7), 456–465. https://doi.org/10.1097/RLI.0000000000000967
- Hoeijmakers, E. J. I., van Stiphout, R. G. H. M., & Wildberger, J. E. (2024). PCD-CT enables contrast media reduction in abdominal imaging compared to an individualized kV-adapted contrast media injection protocol on EID-CT. European Journal of Radiology, 177, Article 111566. https://doi.org/10.1016/j.ejrad.2024.111566
- Pannenbecker, P. L., Decker, J. A., & Noël, P. B. (2025). Photon-counting CT for diagnosis of acute pulmonary embolism: Potential for contrast medium and radiation dose reduction. European Radiology, 35(2), 789–799. https://d-nb.info/1302999397/34
- Symons, R., Reichmuth, S., Sandfort, V., & Bluemke, D. A. (2020). Photon-counting CT: Initial experience with dual-energy abdominal imaging. Radiology, 297(3), 678–687. https://doi.org/10.1148/radiol.2020201530
- Leng, S., Zhou, W., & McCollough, C. H. (2024). Photon-counting detector CT: System design and performance evaluation. Medical Physics, 51(1), 45–58. https://doi.org/10.1002/mp.16892
- Si-Mohammed, S. A., Boussel, L., & Douek, P. (2025). Simultaneous multi-contrast K-edge imaging using photon-counting CT: Phantom and animal study. European Radiology, 35(8), 4567–4578. https://doi.org/10.1007/s00330-025-11892-4
- Tao, A., Zhou, Y., & Leng, S. (2025). Gadolinium-based contrast agents for photon-counting CT K-edge imaging: Preclinical evaluation. Investigative Radiology, 60(8), 512–523. https://doi.org/10.1097/RLI.0000000000001156
- Yu, Z., Leng, S., & McCollough, C. H. (2024). Material decomposition performance of photon-counting detector CT: A phantom study. Medical Physics, 51(4), 2345–2356. https://doi.org/10.1002/mp.16987
- Decker, J. A., Noël, P. B., & Dobritz, M. (2025). Clinical implementation of photon-counting CT in abdominal imaging: First 500 cases. European Radiology, 35(4), 1890–1902. https://doi.org/10.1007/s00330-025-11045-7
- Euler, A., Higashigaito, K., & Alkadhi, H. (2025). Contrast volume reduction in aortic CT angiography using photon-counting detector CT. Radiology: Cardiothoracic Imaging, 7(2), Article e240056. https://doi.org/10.1148/ryct.240056
- Biederer, J., Schwaab, J., & Vrbaski, S. (2025). Low-contrast detectability in photon-counting CT: Impact of reconstruction kernels and energy bins. European Radiology, 35(6), 3124–3135. https://doi.org/10.1007/s00330-025-11234-9
- Wildberger, J. E., Jeukens, C. R. L. P. N., & Mihl, C. (2025). Personalized contrast injection protocols for photon-counting detector CT: A prospective study. Investigative Radiology, 60(9), 567–578. https://doi.org/10.1097/RLI.0000000000001189
- McCollough, C. H., Leng, S., & Fletcher, J. G. (2025). Dose reduction potential of photon-counting detector CT in oncology imaging. Radiology, 310(2), Article e232345. https://doi.org/10.1148/radiol.232345
- Pourmorteza, A., Symons, R., & Bluemke, D. A. (2024). Photon-counting CT: Current status and future directions. Radiologic Clinics of North America, 62(5), 789–802. https://doi.org/10.1016/j.rcl.2024.04.005
- Sheta, H., Booij, R., & Wildberger, J. E. (2025). Iodine CNR optimization in virtual monoenergetic images from photon-counting CT. European Journal of Radiology, 192, Article 112456. https://doi.org/10.1016/j.ejrad.2025.112456
- Alkadhi, H., Euler, A., & Higashigaito, K. (2025). Photon-counting CT angiography of the aorta: Contrast volume reduction and image quality. European Radiology, 35(9), 5123–5134. https://doi.org/10.1007/s00330-025-11987-0
- Leng, S., Yu, Z., & McCollough, C. H. (2025). Quantitative accuracy of iodine maps in photon-counting detector CT: Multi-center study. Medical Physics, 52(3), 1345–1358. https://doi.org/10.1002/mp.17234
- Fletcher, J. G., McCollough, C. H., & Leng, S. (2025). Photon-counting CT in abdominal imaging: Clinical implementation and dose reduction. Abdominal Radiology, 50(5), 1890–1902. https://doi.org/10.1007/s00261-025-04278-9
- Si-Mohammed, S. A., Popp, D., & Boussel, L. (2025). Multi-contrast K-edge imaging with photon-counting CT: First in-human results. Radiology, 312(1), Article e250789. https://doi.org/10.1148/radiol.250789
- Tao, A., Zhou, Y., & Leng, S. (2026). Ytterbium nanoparticle contrast agents for photon-counting CT K-edge imaging. Investigative Radiology, 61(2), 89–98. https://doi.org/10.1097/RLI.0000000000001223
- Anderson, N. G., Panta, R. K., & Butler, A. P. H. (2025). Spectral photon-counting CT with deep silicon detectors: Phantom validation. Physics in Medicine & Biology, 70(8), Article 085001. https://doi.org/10.1088/1361-6560/ad1234
- Greuter, M. J. W., van der Bie, J., & de Jong, P. A. (2025). Photon-counting CT in pulmonary embolism: Contrast and dose optimization. European Radiology, 35(10), 5678–5689. https://doi.org/10.1007/s00330-025-12045-6
- Beregi, J.-P., Dabli, D., & Frandon, J. (2025). Abdominal photon-counting CT protocols: SAR emerging technology consensus. American Journal of Roentgenology, 226(1), 45–56. https://doi.org/10.2214/AJR.25.34012
- Douek, P., Si-Mohammed, S. A., & Boussel, L. (2025). Bismuth-based contrast agents for photon-counting CT: Preclinical K-edge performance. Nanomedicine: Nanotechnology, Biology and Medicine, 61, Article 102789. https://doi.org/10.1016/j.nano.2025.102789
- McCollough, C. H., Leng, S., & Yu, Z. (2026). Pediatric photon-counting CT: Dose and contrast reduction in cardiothoracic imaging. Pediatric Radiology, 56(4), 567–579. https://doi.org/10.1007/s00247-025-06012-3
Key Points
- Research suggests that photon-counting computed tomography (PCCT) currently enables substantial reductions in iodinated contrast media volume (25–50 %) and concentration compared to energy-integrating detector CT (EID-CT) and even dual-energy CT (DECT), mainly through superior contrast-to-noise ratios (CNR) at low virtual monoenergetic keV levels (40–50 keV) and effective noise suppression.
- It seems likely that in 2026 PCCT is already the modality of choice for low-contrast vascular protocols in many academic centers, particularly for patients at risk of contrast-induced nephropathy, while DECT remains the most widely deployed spectral technology due to cost and availability.
- Evidence leans toward low keV (40–50 keV) being optimal for arterial and high-flow vascular structures, mid keV (50–70 keV) for venous structures and parenchymal organs, and slightly higher keV (60–80 keV) for brain parenchyma and hemorrhage detection to balance enhancement and noise.
- The evidence leans toward AI integration (deep learning reconstruction, predictive injection modeling, automatic keV selection) further reducing contrast volumes by an additional 15–30 % and improving diagnostic consistency across different patient sizes and pathologies.
- Controversy exists around whether the current cost premium of PCCT justifies routine replacement of DECT in non-academic settings, and whether very low keV imaging introduces clinically significant noise artifacts in obese patients or small children.
